Sedatives

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Antidepressants, General anesthetics, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine

VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.

Key Points: 
  • VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the Company) is excited to announce that its wholly owned subsidiary Akome Biotech Ltd. (Akome) has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development.
  • The formulation of Akomes breakthrough depression treatment, also known as AKO003, has now been developed and a provisional matter of composition patent application for AKO003 has been filed with the United States Patent and Trademark Office (USPTO) under application 63128302.
  • With the formula finalized the next step is the development of this drug to bring it closer to human trials and an eventual roll out to market.
  • Akomes psychedelic-based drug formulation for the treatment of depression will position Core One as a pioneer in the alternative depression treatment market, stated Joel Shacker, the Companys CEO.

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Retrieved on: 
Tuesday, July 20, 2021
Psychoactive drugs, Psychiatry, Drugs, Psychiatric diagnosis, Abnormal psychology, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Depression, Psilocybin, Major depressive disorder

Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Key Points: 
  • Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami

Retrieved on: 
Friday, July 9, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Wellness, Tristar, Clinical trial

Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.

Key Points: 
  • Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.
  • Dane Jackman, Managing Director of Tristar Wellness, said, This partnership marks the first in a line of Ketamine related micro-trials slated at Tristar Wellness, Miami Beach.
  • Ehave Chief Executive Officer, Ben Kaplan, said, "Hiring an IRB is a very important step in our ketamine clinical Trials in Miami with Tristar Wellness.
  • The safety of the individuals participating in our trials is of utmost importance to both Ehave and Tristar Wellness.

Ketamine One Announces Adam Deffett as Interim CEO

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketamine, Ketones, Sedatives

Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.

Key Points: 
  • Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.
  • Ketamine One has launched on a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
  • I would like to thank Robert for stewarding the transition of the Company from an investment issuer under the name of Myconic Capital Corp. to a company dedicated to mental healthcare and the rebrand to Ketamine One, said Adam Deffett, Interim CEO of Ketamine One.
  • Adam Deffett is a senior capital markets professional with over 15 years of experience in the Canadian equity markets.

Green Science Alliance Has Developed SOFC (Solid Oxide Fuel Cell) Which Can Produce Electricity with Bio-Ethanol

Retrieved on: 
Tuesday, July 6, 2021
Chemical substances, Fuel cells, Energy, Sedatives, Solid oxide fuel cell, Hydrogen economy, Hydrogen technologies, Ethanol fuel, Ethanol, Hydrogen vehicle

KAWANISHI-CITY, Japan, July 6, 2021 /PRNewswire/ -- Green Science Alliance has been developing various types of electrode and solid electrolyte for SOFC.

Key Points: 
  • KAWANISHI-CITY, Japan, July 6, 2021 /PRNewswire/ -- Green Science Alliance has been developing various types of electrode and solid electrolyte for SOFC.
  • This time, Dr. Hideki Yoshioka and Dr. Ryohei Mori at Green Science Alliance have created SOFC which can produce electricity not with hydrogen, but with bio-ethanol.
  • With their experiment, when approximately 33% of ethanol (the rest was water) was used as fuel, created SOFC exhibited approximately 75 - 80% of electric power compared to when pure hydrogen was used as fuel.
  • Carbon deposition on SOFC anodes can be concerned when ethanol is used as fuel.

Leading Psychedelic Wellness Company Delic Completes Acquisition of Ketamine Infusion Centers LLC, Adding Health Clinic Chain to Portfolio

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, OTC Markets Group, WellPet, Delić

VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").
  • KIC will be strategically positioned to leverage DELIC platform and brand: DELIC expects to drive patients to KIC through its media platform and become a national leader
    Established history of providing ketamine infusion services.
  • "The DELIC team is committed to making psychedelic wellness accessible to the masses and with this chain of clinics we are making that vision possible."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Braxia Scientific Announces Participation at PSYCH Investor Summit on July 7, 2021

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Psychiatry, Mind, Psychiatric diagnosis, Abnormal psychology, Psychopathology, Ketamine, Sedatives, Major depressive disorder, Mental disorder, Depression

TORONTO, July 6, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development.

Key Points: 
  • TORONTO, July 6, 2021 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development.
  • Additionally, Dr. McIntyre will discuss Braxia's initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics.
  • For additional information on the conference please visit: https://psych.global/agenda/
    Braxia Scientific , is a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders.
  • The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.

Ehave, Inc. To Be One Of Four Main Sponsors At The Third Annual Psytech Summit on July 19th and 20th, 2021

Retrieved on: 
Friday, July 2, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Clinical research, Chloroarenes, Nicotinic antagonists, Sedatives, Microdosing, Ketamine, Digital therapeutics

The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more.

Key Points: 
  • The third annual PsyTech Summit will cover the most heated topics in the psychedelic sector today, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more.
  • Sponsoring the PsyTech Summit is a great opportunity for Ehave and its shareholders as we roll out our KetaDASH platform and home infusion service, said Ben Kaplan, CEO of Ehave.
  • The third annual Psytech Summit is produced by PsyTech Inc., a leading source of education, clinical care and clinical tools for the fast-growing psychedelic medical sector.
  • Speakers and moderators for the Third Annual Psytech Summit include:
    Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients.

Global Ethanol Bus Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021
Alternative energy, Energy, Alcohols, Chemical substances, Sedatives, Ethanol fuel, Ethanol, Ethanol fuel in the United States, Cellulosic ethanol

The "Ethanol Bus Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ethanol Bus Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Looking forward, the global ethanol bus market to grow at a CAGR of around 10% during 2021-2026.
  • An ethanol bus is a passenger bus that uses ethanol as a fuel source.
  • What is the structure of the global ethanol bus market and who are the key players?

Global Ethyl Alcohol Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Chemicals, Plastics, Automotive, Oil, Gas, Manufacturing, Energy, Alternative Vehicles, Fuels, Alcohols, Chemical substances, Sedatives, Ethanol fuel, Petroleum products, Liquid fuels, Ethanol, Gasoline, Ethanol fuel in Brazil, Common ethanol fuel mixtures

Carbon monoxide production from ethanol fuel is significantly lower when compared to gasoline engines.

Key Points: 
  • Carbon monoxide production from ethanol fuel is significantly lower when compared to gasoline engines.
  • Moreover, for the past several years, refiners have been adding ethanol to fuel, as it burns cleaner than pure gas, which helps in cutting the carbon footprint.
  • In Brazil, fuel ethanol consumption is driven largely by an ethanol blending mandate and lower prices relative to gasoline.
  • Growing demand for premium skin care products, along with the need for a better lifestyle, is driving the market for personal care in the country, positively impacting the demand for ethyl alcohol.